Article

Inspire Pharmaceuticals to commercialize InSite Vision antibiotic if approved

Durham, NC-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.’s 1% azithromycin topical anti-infective product (AzaSite) in the United States and Canada under the terms of a licensing agreement signed by the two companies. The product is under new device application review by the FDA for the treatment of bacterial conjunctivitis.

Durham, NC-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.’s 1% azithromycin topical anti-infective product (AzaSite) in the United States and Canada under the terms of a licensing agreement signed by the two companies. The product is under new device application review by the FDA for the treatment of bacterial conjunctivitis.

The broad-spectrum antibiotic is formulated with InSite’s patented drug-delivery vehicle (DuraSite). If approved, it is anticipated that the product will become the first ocular antibiotic with a once-daily dosing regimen after an initial loading dose. The companies say the dosing schedule may increase patient adherence and therapeutic efficacy.

The agreement calls for Inspire to pay InSite an upfront license fee of $13 million and an additional $19 million payment contingent on regulatory approval by the FDA. Inspire also will pay a royalty-20% on net sales in the first 2 years of commercialization and 25% thereafter-on net sales of the antibiotic in the United States and Canada, if approved by regulatory authorities.

The collaboration “will allow us to pursue additional anti-infective products and indications worldwide,” said S. Kumar Chandrasekaran, PhD, chief executive officer of InSite, based in Alameda, CA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.